Abstract
Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have